Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,149.95 -1,181.38 (-1.84%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
Nuvalent, Inc. (NUVL)
After hours:
| Previous close | 66.07 |
| Open | 66.66 |
| Bid | 66.64 x 100 |
| Ask | 66.87 x 100 |
| Day's range | 65.11 - 66.89 |
| 52-week range | 35.29 - 89.39 |
| Volume | |
| Avg. volume | 480,906 |
| Market cap | 4.284B |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.17 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 101.50 |
PR NewswireNuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data for its novel HER2-selective inhibitor, NVL-330, and novel ROS1-selective inhibitor, zidesamtinib (NVL-520). The two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5 – 10 in San Diego. The posters wi
GuruFocus.comChief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)
Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted therapies for patients with cancer, has reported an insider sale according to a recent SEC filing.
Barrons.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
